We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Molecular Pharmacology Limited (PK) | USOTC:MLPH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0006 | 0.0006 | 0.0006 | 0.00 | 01:00:00 |
OMB APPROVAL |
OMB Number: 3235-0070 |
Expires: April 30, 2015 |
Estimated average burden
hours per response: ...........187.43 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q /A-1
i
ii
MOLECULAR PHARMACOLOGY (USA) LIMITED
Form 10-Q-Amendment No. 1
Explanatory Note
We are filing this Amendment No. 1 (" Form 10-Q/A-1 ") to our Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2013, originally filed with the Securities and Exchange Commission (the " SEC ") on May 8, 2013 (the " Form 10-Q ") in order to file the interactive data files in XBRL format required by Rule 405 of Regulation S-T and Item 601 of Regulation S-K. These XBRL documents did not attach properly to the Form 10-Q filing.
In accordance with Rule 12b-15 under the Securities Exchange Act of 1934 , as amended, each item of the Form 10-Q that is amended by this Form 10-Q/A-1 is restated in its entirety, and this Form 10-Q/A-1 is accompanied by currently dated certifications on Exhibits 31.1, 31.2, and 32.1 by our Chief Executive Officer and Chief Financial Officer.
Except as expressly set forth in this Form 10-Q/A-1, we are not amending any other part of the Form 10-Q. This Form 10-Q/A-1 does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures, including forward-looking statements, unless expressly noted otherwise. Accordingly, this Form 10-Q/A-1 should be read in conjunction with the Form 10-Q and with our other filings made with the SEC subsequent to the filing of the Form 10-Q, including any amendments to those filings.
For reference purposes only, the index to exhibits related to Exhibit 101 (for interactive data files) is set forth below.
INDEX TO EXHIBITS
These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K:
Exhibit | ||
Number | Description | |
101.INS
|
XBRL Instance Document. | |
|
||
101.SCH
|
XBRL Taxonomy Extension Schema. | |
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase | |
|
||
101.LAB
|
XBRL Taxonomy Extension Labels Linkbase. | |
|
||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
May 8, 2013.
MOLECULAR PHARMACOLOGY (USA) LIMITED
|
||
BY: |
/s/ Jeffery Edwards |
|
|
Jeffery Edwards, President, Chief Executive Officer, Chief Financial Officer and a Member of the Board of Directors |
|
|
||
|
1
1 Year Molecular Pharmacology (PK) Chart |
1 Month Molecular Pharmacology (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions